Appendix 3B – Issue of shares under Share Purchase Plan
Telix Pharmaceuticals Ltd is pleased to announce Appendix 3B – Issue of shares under Share Purchase Plan…
Read moreNews & Views
First Australian Patient Dosed in ZIRCON Phase III Trial
Telix Pharmaceuticals Limited is pleased to announce that the first Australian patient has been added to the Phase III ZIRCON study. The first Australian patient was dosed with TLX250-CDx at…
Read more
Telix Pharmaceuticals Announces Results of Successful SPP
Telix Pharmaceuticals Limited is pleased to advise that, at closing on Friday 16th August 2019, subscriptions under the Company’s Share Purchase Plan (“SPP”) totaled approximately $9.6…
Read more
Telix Pharmaceuticals to Present at Jefferies Healthcare Conference
Telix Pharmaceuticals is pleased to announce Telix’s CEO, Dr. Christian Behrenbruch will present at the Jefferies Healthcare Conference at the Grand Hyatt Hotel in New York at 8:00 AM EDT…
Read more
Telix Pharmaceuticals Annual Report 2018
Telix Pharmaceuticals Limited is pleased to provide its Annual Report…
Read more
Telix Pharmaceuticals launches information site on illumet™ prostate cancer imaging product
Telix has just launched an information site on our illumet™ prostate cancer imaging product. The website provides an informative depository about how the product works and its potential in clinical…
Read more
Strategy Update – Acceleration of Prostate Cancer Therapy Program
Telix Pharmaceuticals Limited today announced a strategy update for the TLX591 (prostate therapy)…
Read more
Telix Pharmaceuticals Ltd Detailed Program Update January 2019
Telix Pharmaceuticals Limited is pleased to provide a detailed Program Update January…
Read more
Telix Pharmaceuticals & Radboud University Medical Centre Conclude Clinical Collaboration Agreement
Telix Pharmaceuticals has today announced a clinical collaboration with Radboud University Medical…
Read more